{"id":{"repo_id":"denver","oai_identifier":"oai:digitalcommons.du.edu:etd-1647"},"canonical_url":"https://search.ndltd.org/etd/denver/oai:digitalcommons.du.edu:etd-1647","repository":{"repo_id":"denver","name":"University of Denver","base_url":"https://digitalcommons.du.edu/do/oai/"},"display":{"title":"The Case for Extending Patent Terms for Drugs That Treat Rare Diseases","abstract":"This paper seeks to determine if extended patent terms can positively effect the production of drugs that treat rare diseases. It reviews the structure of the modern pharmaceutical company and considers the regulatory history that lead to this structure. The paper applies historically significant economic research in the field of patents and considers patent alternatives to establish the best method for incentivizing the development of these drugs. The paper finds that while there are numerous pitfalls and issues with the patent method, there are no viable alternatives. It also concludes that extending patent terms for drugs that treat rare diseases can act as a catalyst to orphan drug development.","abstract_html":"This paper seeks to determine if extended patent terms can positively effect the production of drugs that treat rare diseases. It reviews the structure of the modern pharmaceutical company and considers the regulatory history that lead to this structure. The paper applies historically significant economic research in the field of patents and considers patent alternatives to establish the best method for incentivizing the development of these drugs. The paper finds that while there are numerous pitfalls and issues with the patent method, there are no viable alternatives. It also concludes that extending patent terms for drugs that treat rare diseases can act as a catalyst to orphan drug development.","abstract_has_math":false,"creators":["Thompson, Joanna Louise"],"institution":null,"degree_name":"M.A.","degree_level":"Masters Thesis","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Peter Ho, Ph.D.","Markus Schneider","Yavuz Yasar"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T07:53:50Z","subjects":["Drug","Patent","Pharmaceutical","Chemicals and Drugs","Economics"],"languages":["en"],"rights":["<p>Copyright is held by the author. User is responsible for all copyright compliance.</p>","Joanna Louise Thompson"],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.du.edu/etd/648","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.du.edu/etd/648","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.du.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.du.edu%3Aetd-1647","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Peter Ho, Ph.D.","Markus Schneider","Yavuz Yasar"]},{"key":"dc:creator","label":"Author","values":["Thompson, Joanna Louise"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2001-01-01T08:00:00Z"]},{"key":"dc:date.copyright","label":"Dc Date Copyright","values":["2013-01-01T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-01-01T08:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Masters Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.A."]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Drug","Patent","Pharmaceutical","Chemicals and Drugs","Economics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["<p>Copyright is held by the author. User is responsible for all copyright compliance.</p>"]},{"key":"dc:rights.holder","label":"Dc Rights Holder","values":["Joanna Louise Thompson"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.du.edu/etd/648"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This paper seeks to determine if extended patent terms can positively effect the production of drugs that treat rare diseases. It reviews the structure of the modern pharmaceutical company and considers the regulatory history that lead to this structure. The paper applies historically significant economic research in the field of patents and considers patent alternatives to establish the best method for incentivizing the development of these drugs. The paper finds that while there are numerous pitfalls and issues with the patent method, there are no viable alternatives. It also concludes that extending patent terms for drugs that treat rare diseases can act as a catalyst to orphan drug development."]},{"key":"dc:description.provenance","label":"Dc Description Provenance","values":["Received from ProQuest"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:format.extent","label":"Dc Format Extent","values":["100 p."]},{"key":"dc:title","label":"Title","values":["The Case for Extending Patent Terms for Drugs That Treat Rare Diseases"]}]}],"canonical_facts":{"dc:contributor":["Peter Ho, Ph.D.","Markus Schneider","Yavuz Yasar"],"dc:creator":["Thompson, Joanna Louise"],"dc:date.available":["2001-01-01T08:00:00Z"],"dc:date.copyright":["2013-01-01T08:00:00Z"],"dc:date.created":["2013-01-01T08:00:00Z"],"dc:description.abstract":["This paper seeks to determine if extended patent terms can positively effect the production of drugs that treat rare diseases. It reviews the structure of the modern pharmaceutical company and considers the regulatory history that lead to this structure. The paper applies historically significant economic research in the field of patents and considers patent alternatives to establish the best method for incentivizing the development of these drugs. The paper finds that while there are numerous pitfalls and issues with the patent method, there are no viable alternatives. It also concludes that extending patent terms for drugs that treat rare diseases can act as a catalyst to orphan drug development."],"dc:description.provenance":["Received from ProQuest"],"dc:format":["application/pdf"],"dc:format.extent":["100 p."],"dc:identifier":["https://digitalcommons.du.edu/etd/648"],"dc:language":["en"],"dc:rights":["<p>Copyright is held by the author. User is responsible for all copyright compliance.</p>"],"dc:rights.holder":["Joanna Louise Thompson"],"dc:subject":["Drug","Patent","Pharmaceutical","Chemicals and Drugs","Economics"],"dc:title":["The Case for Extending Patent Terms for Drugs That Treat Rare Diseases"],"thesis:degree_level":["Masters Thesis"],"thesis:degree_name":["M.A."]},"updated_at":"2026-11-19T07:53:50Z"}